CN113896787A - 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途 - Google Patents

表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途 Download PDF

Info

Publication number
CN113896787A
CN113896787A CN202111171021.6A CN202111171021A CN113896787A CN 113896787 A CN113896787 A CN 113896787A CN 202111171021 A CN202111171021 A CN 202111171021A CN 113896787 A CN113896787 A CN 113896787A
Authority
CN
China
Prior art keywords
antibody
expression
nucleic acid
promoter
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111171021.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·许尔斯曼
H·克内根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN113896787A publication Critical patent/CN113896787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202111171021.6A 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途 Pending CN113896787A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11195361.8 2011-12-22
EP11195361 2011-12-22
CN201280062793.9A CN104011075B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280062793.9A Division CN104011075B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途

Publications (1)

Publication Number Publication Date
CN113896787A true CN113896787A (zh) 2022-01-07

Family

ID=47504950

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111171021.6A Pending CN113896787A (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN201710324350.7A Pending CN107119073A (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN201280062793.9A Active CN104011075B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN202111170578.8A Active CN113881702B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201710324350.7A Pending CN107119073A (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN201280062793.9A Active CN104011075B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN202111170578.8A Active CN113881702B (zh) 2011-12-22 2012-12-19 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途

Country Status (14)

Country Link
US (2) US20160208284A1 (https=)
EP (2) EP2794651B1 (https=)
JP (4) JP6096802B2 (https=)
KR (4) KR102285184B1 (https=)
CN (4) CN113896787A (https=)
BR (1) BR112014014239B1 (https=)
CA (2) CA3149402A1 (https=)
ES (1) ES2930215T3 (https=)
HR (1) HRP20221383T1 (https=)
MX (2) MX370481B (https=)
PL (1) PL2794651T3 (https=)
RU (2) RU2639519C2 (https=)
SG (3) SG10201900915WA (https=)
WO (1) WO2013092743A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201900915WA (en) * 2011-12-22 2019-03-28 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP3683314A1 (en) * 2013-10-07 2020-07-22 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN105255867A (zh) * 2015-10-19 2016-01-20 北京益生合生物科技有限公司 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
KR102712926B1 (ko) 2016-10-20 2024-10-07 상가모 테라퓨틱스, 인코포레이티드 파브리병의 치료를 위한 방법 및 조성물
JP7282689B2 (ja) * 2017-05-19 2023-05-29 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチ リフォールディングした組み換えヒト化ラニビズマブの製造方法
JP7081139B2 (ja) * 2017-12-20 2022-06-07 東ソー株式会社 新規プロモーターおよびそれを含む発現ベクター
CN113015801A (zh) * 2018-09-20 2021-06-22 赛诺菲 基于内含子的通用克隆方法和组合物
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
JP7250950B2 (ja) 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー 所定の構成の複数の発現カセットを標的指向組込みすることによってＦｃＲｎ発現細胞を作製するための方法
KR102798616B1 (ko) 2019-12-20 2025-04-22 (주)셀트리온 목적 단백질의 고발현을 위한 인트론을 포함하는 발현 카세트 및 이의 이용
US20240066149A1 (en) * 2021-01-12 2024-02-29 Jcr Pharmaceuticals Co., Ltd. Nucleic Acid Molecule Containing Incorporated Gene Encoding Fused Protein of Ligand and Protein Having Physiological Activity
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
US20240252619A1 (en) * 2021-05-21 2024-08-01 The Regents Of The University Of California Coronavirus Constructs and Vaccines
US20250197888A1 (en) * 2022-03-24 2025-06-19 Cell & Brain Co., Ltd. Novel recombinant vector and use thereof
WO2024239229A1 (zh) * 2023-05-23 2024-11-28 西安佑佰生物科技有限公司 一种增强相邻启动子转录活性的载体及其方法
KR102640929B1 (ko) 2023-06-02 2024-02-27 (주) 멥스젠 미세생체조직시스템 형성 장치

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142124A1 (en) * 2007-05-21 2008-11-27 Vivalis Recombinant protein production in avian ebx® cells
CN101517085A (zh) * 2006-07-26 2009-08-26 贝林格尔英格海姆法玛两合公司 调控性核酸元件

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
RU2201449C2 (ru) * 1994-10-14 2003-03-27 Сембайозис Дженетикс Инк. Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes
MXPA04004634A (es) * 2001-11-16 2004-08-12 Idec Pharma Corp Expresion policistronica de anticuerpos.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
SI2116605T1 (sl) * 2004-06-17 2012-07-31 Wyeth Llc Plazmid s tremi popolnimi transkripcijskimi enotami in imunogeni sestavki za induciranje imunskega odgovora na HIV
US7807409B2 (en) * 2005-10-21 2010-10-05 Roche Palo Alto Llc Method for the recombinant expression of a polypeptide
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
EP2099914A1 (en) * 2006-12-22 2009-09-16 F. Hoffmann-Roche AG Selection method
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
NZ580378A (en) * 2007-03-30 2012-11-30 Abbott Lab Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
MX2009013120A (es) * 2007-06-29 2010-01-15 Hoffmann La Roche Promotor.
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
AU2009286956B2 (en) * 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
SG10201900915WA (en) * 2011-12-22 2019-03-28 Hoffmann La Roche Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101517085A (zh) * 2006-07-26 2009-08-26 贝林格尔英格海姆法玛两合公司 调控性核酸元件
WO2008142124A1 (en) * 2007-05-21 2008-11-27 Vivalis Recombinant protein production in avian ebx® cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PAUL WINNARD等: "Robust expression of transgenes in MCF-7 breast cancer cells is expression vector-dependent", BIOTECHNIQUES, vol. 37, 30 September 2004 (2004-09-30), pages 1 - 3 *
PIETRO P. SANNA: "Expression of Antibody Fab Fragments and Whole Immunoglobulin in Mammalian Cells", METHODS IN MOLECULAR BIOLOGY, vol. 178, 31 December 2002 (2002-12-31), pages 1 - 3 *
元英进: "现代制药工艺学", vol. 1, 31 July 2004, 化学工业出版社, pages: 234 - 235 *
杨安钢等: "生物化学与分子生物学实验技术", vol. 1, 30 June 2008, 高等教育出版社, pages: 118 - 119 *

Also Published As

Publication number Publication date
CN107119073A (zh) 2017-09-01
SG11201403443WA (en) 2014-07-30
MX2014007359A (es) 2014-08-01
CA3149402A1 (en) 2013-06-27
US20210024952A1 (en) 2021-01-28
JP2015500656A (ja) 2015-01-08
CN104011075A (zh) 2014-08-27
KR20140106585A (ko) 2014-09-03
KR20200032240A (ko) 2020-03-25
HRP20221383T1 (hr) 2023-01-06
EP2794651A2 (en) 2014-10-29
KR102285184B1 (ko) 2021-08-03
MX370481B (es) 2019-12-16
CA2854249A1 (en) 2013-06-27
MX355624B (es) 2018-04-25
WO2013092743A3 (en) 2013-10-03
WO2013092743A2 (en) 2013-06-27
JP6417436B2 (ja) 2018-11-07
JP2019030311A (ja) 2019-02-28
EP3354660A1 (en) 2018-08-01
HK1200848A1 (en) 2015-08-14
RU2017140661A (ru) 2019-02-12
CN104011075B (zh) 2017-06-06
RU2756910C2 (ru) 2021-10-06
ES2930215T3 (es) 2022-12-07
CN113881702B (zh) 2025-05-30
KR102166824B1 (ko) 2020-10-19
JP6096802B2 (ja) 2017-03-15
RU2017140661A3 (https=) 2021-08-09
US20160208284A1 (en) 2016-07-21
RU2014129727A (ru) 2016-02-20
JP7096806B2 (ja) 2022-07-06
KR102048556B1 (ko) 2019-11-26
JP2017108753A (ja) 2017-06-22
CN113881702A (zh) 2022-01-04
CA2854249C (en) 2022-05-03
KR102229491B1 (ko) 2021-03-18
JP2020054372A (ja) 2020-04-09
BR112014014239B1 (pt) 2021-10-13
EP2794651B1 (en) 2022-09-21
PL2794651T3 (pl) 2022-12-27
SG10201900915WA (en) 2019-03-28
SG10201700169PA (en) 2017-02-27
KR20210031002A (ko) 2021-03-18
RU2639519C2 (ru) 2017-12-21
KR20190132702A (ko) 2019-11-28
BR112014014239A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
CN113881702B (zh) 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
HK1250743A1 (zh) 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
AU2020306672B2 (en) Mammalian cell lines with SIRT-1 gene knockout
AU2020294880B2 (en) Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
JP2024026208A (ja) 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法
JP2025134010A (ja) 所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
JP2024167256A (ja) 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法
KR20220010019A (ko) 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 2가 이중특이성 항체 발현 세포를 생성하는 방법
CN116391037A (zh) 具有基因敲除的哺乳动物细胞系
HK40059294A (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
HK40059284A (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
HK40059284B (zh) 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
HK1238674A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
HK40092505A (zh) 具有基因敲除的哺乳动物细胞系
HK1200848B (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40059294

Country of ref document: HK